http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-112946299-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-368 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6854 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2022-11-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-112946299-B |
| titleOfInvention | Application of quantitative FTL products in the preparation of diagnostic tools for preeclampsia |
| abstract | The invention discloses the application of a quantitative FTL product in the preparation of a diagnostic tool for preeclampsia. The present invention carries out laboratory verification after quantitative proteomics analysis, and finds for the first time that the expression levels of FTL in the placenta of pregnant women with PE and plasma in late pregnancy are significantly reduced. The present invention proposes the application of FTL as a novel biomarker of PE in the preparation of a PE diagnostic tool, and when a decrease in FTL level is detected, the occurrence of PE can be indicated. The application of reagents for quantifying FTL levels in the clinical diagnosis of PE is a supplement to existing research. The invention not only provides a new idea for research on PE diagnosis, but also helps to further develop new drugs for preventing or treating PE. |
| priorityDate | 2021-01-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 78.